Title |
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate
|
---|---|
Published in |
Journal of Pharmaceutical Policy and Practice, April 2016
|
DOI | 10.1186/s40545-016-0062-x |
Pubmed ID | |
Authors |
Agnes Vitry, Barbara Mintzes, Wendy Lipworth |
Abstract |
Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical industry often make claims of delayed or lack of access to new cancer medicines-claims that are frequently supported by prominent coverage in the Australian media. These claims, while morally and psychologically compelling, tend to ignore the complexity of medicines funding decisions. In this commentary we summarise the current situation regarding the registration and funding of cancer medicines in Australia, elucidate the main challenges associated with access to cancer medicines in the Australian context, and describe some of the steps that have been taken to address these challenges. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 50% |
United States | 1 | 25% |
Canada | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 50% |
Members of the public | 1 | 25% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 23% |
Student > Master | 5 | 19% |
Student > Doctoral Student | 3 | 12% |
Student > Postgraduate | 3 | 12% |
Student > Ph. D. Student | 2 | 8% |
Other | 3 | 12% |
Unknown | 4 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 38% |
Economics, Econometrics and Finance | 4 | 15% |
Social Sciences | 2 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Other | 3 | 12% |
Unknown | 4 | 15% |